Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS

Neurology. 2004 Jan 27;62(2):282-4. doi: 10.1212/wnl.62.2.282.


The authors report the outcome of 14 patients with severe multiple sclerosis treated with autologous hematopoietic stem cell transplantation (AHSCT) after a median follow-up period of 3 years. The 3-year actuarial probability of progression-free survival was 85.7% and that of disease activity-free survival was 46.4%. On MRI, no T1-enhanced lesions were detected after AHSCT. The mean change in T2 lesion volume from baseline to the third year was -20.2% and that of the corpus callosum area was -12.7%; 50% of this reduction was seen during the first year.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actuarial Analysis
  • Adult
  • Atrophy
  • Brain / pathology
  • Corpus Callosum / pathology
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Hematopoietic Stem Cell Mobilization
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Magnetic Resonance Imaging*
  • Male
  • Middle Aged
  • Multiple Sclerosis / pathology
  • Multiple Sclerosis / therapy*
  • Prospective Studies
  • Transplantation Conditioning / adverse effects
  • Transplantation, Autologous
  • Treatment Outcome